Loading…
The patent is for a noninvasive lung cancer diagnostic.
bioAffinity Technologies, Inc. (Nasdaq: BIAF) announced it has been granted a patent in Hong Kong for its CyPath® Lung, a noninvasive diagnostic test for lung cancer. The announcement was made following the official grant by the Hong Kong Intellectual Property Department.
The patent covers bioAffinity's technology that uses fluorescence in situ hybridization to detect lung cancer cells in sputum samples. This method allows for early detection of lung cancer without the need for invasive procedures.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.